4D Molecular Therapeutics Appoints John F. Milligan, Ph.D., as Executive Chairman of Board of Directors

EMERYVILLE, Calif.--(BUSINESS WIRE)--4D Molecular Therapeutics (4DMT), a clinical-stage leader in the development of precision-guided AAV gene therapy based on directed evolution, announced the appointment of John F. Milligan, Ph.D. as Executive Chairman of the Board of Directors. “I believe John is the best possible partner I could hope for in our mission to take 4DMT to the highest levels of success in business and in bringing transformative treatments to patients,” said David Kirn, MD, co-fo

Click to view original post